Loading
A phase 1/2 trial of Olomorasib, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin in non-small-cell lung cancer, colorectal cancer, endometrial cancer, ovarian cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, run by Eli Lilly and Company, active and no longer recruiting.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) is a phase 1/2 interventional study registered as NCT04956640 by Eli Lilly and Company, with 540 participants enrolled, started 2021-07-19 and due to reach its primary completion in 2027-04. Interventions recorded: LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin and Carboplatin.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Merck & Co. (MSD), Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Endometrial cancer, Biliary tract cancer (cholangiocarcinoma), Ovarian cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Pemetrexed, Merck & Co. (MSD), Cisplatin, Carboplatin and the tag pipeline.